MedTrace Logo

Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care

NCT05474157 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-07-26

No results posted yet for this study

Summary

The primary aim of this study is to evaluate the patients who had pneumonia or severe acute respiratory distress syndrome (ARDS) due to COVID-19 in terms of sarcopenia and related factors following Intensive Care Unit (ICU).

The patients who had COVID-19 infection in the ICU and the patients who admitted to the 'Physical Medicine and Rehabilitation' clinic for other reasons during the pandemic period will be compared in terms of sarcopenia.

Conditions

  • Sarcopenia
  • Covid19
  • Intensive Care Unit Acquired Weakness

Interventions

OTHER

Standard care treatment for COVID-19 in Intensive Care Unit

Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.

Sponsors & Collaborators

  • Koç University

    lead OTHER

Principal Investigators

  • Ozden Ozyemisci Taskiran, Prof · Koc University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-01-01
Completion
2022-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05474157 on ClinicalTrials.gov